Pathophysiology of NASH: perspectives for a targeted treatment. - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Current Pharmaceutical Design Year : 2013

Pathophysiology of NASH: perspectives for a targeted treatment.


Non alcoholic steatohepatitis (NASH) is the more severe form of nonalcoholic fatty liver disease. In NASH, fatty liver, hepatic inflammation, hepatocyte injury and fibrogenesis are associated, and this condition may eventually lead to cirrhosis. Current treatment of NASH relies on the reduction of body weight and increase in physical activity, but there is no pharmacologic treatment approved as yet. Emerging data indicate that NASH progression results from parallel events originating from the liver as well as from the adipose tissue, the gut and the gastrointestinal tract. Thus, dysfunction of the adipose tissue through enhanced flow of free fatty acids and release of adipocytokines, and alterations in the gut microbiome generate proinflammatory signals that underlie NASH progression. Additional 'extrahepatic hits' include dietary factors and gastrointestinal hormones. Within the liver, hepatocyte apoptosis, ER stress and oxidative stress are key contributors to hepatocellular injury. In addition, lipotoxic mediators and danger signals activate Kupffer cells which initiate and perpetuate the inflammatory response by releasing inflammatory mediators that contribute to inflammatory cell recruitment and development of fibrosis. Inflammatory and fibrogenic mediators include chemokines, the cannabinoid system, the inflammasome and activation of pattern-recognition receptors. Here we review the major mechanisms leading to appearance and progression of NASH, focusing on both extrahepatic signals and local inflammatory mechanisms, in an effort to identify the most promising molecular targets for the treatment of this condition.
Fichier principal
Vignette du fichier
inserm-00801356_edited.pdf (537.88 Ko) Télécharger le fichier
Marra_and_Lotersztajn_Current_Pharmaceutical_Design.pdf (1.65 Mo) Télécharger le fichier
Origin Files produced by the author(s)
Origin Files produced by the author(s)

Dates and versions

inserm-00801356 , version 1 (15-03-2014)


  • HAL Id : inserm-00801356 , version 1
  • PUBMED : 23394092


Fabio Marra, Sophie Lotersztajn. Pathophysiology of NASH: perspectives for a targeted treatment.. Current Pharmaceutical Design, 2013, 19 (29), pp.5250-69. ⟨inserm-00801356⟩


334 View
920 Download



Gmail Mastodon Facebook X LinkedIn More